Gilead Sciences (BMV:GILD *) - Stock Price, News & Analysis

GILD * Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

About the company

GILD * fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	4/6
Financial Health	4/6
Dividends	3/6

Rewards

Trading at 51.6% below our estimate of its fair value

Earnings are forecast to grow 10.03% per year

Earnings grew by 23.4% over the past year

Analysts in good agreement that stock price will rise by 27.7%

Risk Analysis

Shares are highly illiquid

Unstable dividend track record

Has a high level of debt

Large one-off items impacting financial results

Gilead Sciences, Inc. Competitors

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$96.4b

CSL

ASX:CSL

AU$130.2b

Vertex Pharmaceuticals

NasdaqGS:VRTX

US$101.9b

Amgen

NasdaqGS:AMGN

US$144.2b

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share Price	US$1,129.86
52 Week High	US$1,551.92
52 Week Low	US$1,129.86
Beta	0.20
1 Month Change	-8.19%
3 Month Change	-16.31%
1 Year Change	-27.37%
3 Year Change	-13.09%
5 Year Change	-5.46%
Change since IPO	301.02%

Recent updates

Shareholder Returns

	GILD *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	-27.4%	0%	0%

Return vs Industry: GILD * underperformed the MX Biotechs industry which returned -8% over the past year.

Return vs Market: GILD * underperformed the MX Market which returned 0.6% over the past year.

Price Volatility

Is GILD *'s price volatile compared to industry and market?
GILD * volatility
GILD * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: GILD *'s share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine GILD *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	18,000	Dan O'Day	www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD * fundamental statistics
Market cap	Mex$1.43t
Earnings (TTM)	Mex$96.98b
Revenue (TTM)	Mex$464.18b

14.7x

P/E Ratio

3.1x

P/S Ratio

Is GILD * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GILD * income statement (TTM)
Revenue	US$27.12b
Cost of Revenue	US$6.02b
Gross Profit	US$21.10b
Other Expenses	US$15.43b
Earnings	US$5.67b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)	4.54
Gross Margin	77.80%
Net Profit Margin	20.89%
Debt/Equity Ratio	109.8%

How did GILD * perform over the long term?

See historical performance and comparison

Dividends

4.6%

Current Dividend Yield

66%

Payout Ratio

GILD * Stock Overview

Rewards

Risk Analysis

Gilead Sciences, Inc. Competitors

NasdaqGS:REGN

US$96.4b

ASX:CSL

AU$130.2b

NasdaqGS:VRTX

US$101.9b

NasdaqGS:AMGN

US$144.2b

Price History & Performance

Recent News & Updates

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Insufficient new directors

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Recent updates

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Insufficient new directors

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Upcoming dividend of US$0.77 per share

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Fourth quarter dividend of US$0.77 announced

New minor risk - Financial position

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Insufficient new directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Insufficient new directors

Third quarter 2023 earnings released: EPS: US$1.75 (vs US$1.43 in 3Q 2022)

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Gilead Sciences, Inc. to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting®? 2023

Insufficient new directors

Gilead Sciences, Inc. Presents New Data Supporting Sunlenca®? (Lenacapavir) as an Important Treatment Option for Adults with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces New Long-Term Real-World Data from BICSTaR Study Highlighting Safety and Efficacy Profile of Biktarvy as Treatment Regimen for Broad Range of People with HIV, Including Those with Prior Treatment History or Comorbidities

Gilead Sciences, Inc. Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Purpose Program

Gilead Demonstrates the Impact of Global Collaboration in Advancing Hiv Research and Health Equity At EACS 2023

Gilead Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of US$0.75 per share at 4.0% yield

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.84 (vs US$0.91 in 2Q 2022)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

European Commission Approves Gilead’S Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial

Gilead Sciences, Inc. Presents New Biktarvy® Data at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Announces Week 96 Results from the Pivotal MYR301 Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepatitis Delta

Upcoming dividend of US$0.75 per share at 3.9% yield

Gilead Sciences, Inc. Announces Longer-Term Overall Survival Results from the Phase 3 Tropics-02 Study Evaluating Trodelvy® Versus Comparator Chemotherapy

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Bloom Science, Inc. Appoints Grace E. Colon as Chair of Its Board of Directors

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care At Asco 2023

Gilead Sciences, Inc. Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences, Inc. (NasdaqGS:GILD) acquired Xinthera, Inc.

First quarter 2023 earnings released: EPS: US$0.81 (vs US$0.015 in 1Q 2022)

Upcoming dividend of US$0.75 per share at 3.7% yield

Shareholder Returns

Price Volatility